Drug Profile
Research programme: antibacterials - PepTx
Alternative Names: Anti-infectives - PepTx; Antimicrobials - PepTx; Prosep; PTX 002; PTX 005; PTX 006; PTX 007; PTX 010; SC4 - PepTx; Sepsis therapies - PepTxLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer PepTx; University of Minnesota
- Class Peptides; Small molecules
- Mechanism of Action Cell membrane permeability enhancers; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Sepsis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Sepsis in USA (Parenteral)
- 25 Mar 2008 Preclinical development is ongoing